Status:

UNKNOWN

Renal Denervation in Patients With Type 2 Diabetes Mellitus

Lead Sponsor:

Zhongda Hospital

Conditions:

Type 2 Diabetes Mellitus

Renal Denervation

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

Sympathetic overactivity induces insulin resistance and type 2 diabetes mellitus (T2DM), so we assume that renal denervation (RDN) might improve glucose metabolism and insulin sensitivity. The purpose...

Detailed Description

Sympathetic overactivity induces insulin resistance and type 2 diabetes mellitus (T2DM), so it is assumed that renal denervation (RDN) might improve glucose metabolism and insulin sensitivity. Some cl...

Eligibility Criteria

Inclusion

  • Over 18 years and ≤ 70 years old
  • Able and willing to provide informed consent
  • Patients with established type II diabetes mellitus (HbA1C\>7.5%, diet or oral hypoglycaemic agents)
  • Clinical stable as demonstrated by no change in background anti-diabetic medication in the last 30 days.
  • Anticipated that patients are able to maintain a stable dose of medication for the duration of the study

Exclusion

  • Renal arterial anatomy ineligible for RDN: main renal arteries \<4 mm in diameter or \<20 mm in treatable length; multiple renal arteries where main renal artery is estimated to supply \<75% of the kidney
  • History of prior renal artery intervention including balloon angioplasty, stenting or previous renal denervation
  • Type 1 diabetes mellitus
  • Pregnant, nursing or planning to be pregnant
  • Orthostatic hypotension
  • eGFR \<30 ml/min (MDRD formula)
  • Patients that have allergy to contrast agent
  • Myocardial infarction, unstable angina pectoris, coronary bypass or percutaneous angioplasty within 3 months before inclusion
  • Cerebrovascular accidents and alimentary tract hemorrhage within 3 months before inclusion
  • Any medical condition which, in the investigators opinion, may adversely affect the participants safety in the trial

Key Trial Info

Start Date :

January 18 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2022

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT03418415

Start Date

January 18 2018

End Date

January 1 2022

Last Update

February 1 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Zhongda Hospital, Southeast University

Nanjing, Jiangsu, China, 210009